Diagnostic and Patient Management Study (DPMS)
- Eight sites across Europe:
- UNIGE – Geneva (Switzerland)
- VUmc – Amsterdam (Netherlands)
- CHUT – Toulouse (France)
- UKK – Cologne (Germany)
- BBRC – Barcelona (Spain)
- UCL – London (UK)
- CHUV – Lausanne (Switzerland)
- KI – Stockholm (Sweden)
- 844 participants recruited in AMYPAD DPMS (854 scans performed including 114 repeated scans).
- Recruitment ended on 30th October 2020.
- All scans and visits were completed by end of June 2021.
- All sites have been monitored and closed.
Prognostic and Natural History Study (PNHS)
- 6 activated Wave-1 sites: VUMC, UEDIN, BBRC, CHUT, UNIGE, KI
- 11 activated Wave-2 sites: Montpellier (France), NHS TAYSIDE (UK), Paris la Pitié Salpêtrière (France), UZ Leuven (Belgium), Paris Nord (France), Nantes (France), CITA (Spain), Fundacio ACE (Spain), Lille (France), UC Louvain (Belgium), UGOT (Sweden)
- To date 6 sites are done with the recruitment and scanning of their participants (UEDIN, Tayside, CHUT, Nantes, Paris la Pitié and Fundació ACE)
- 10 Parent Cohorts actively enrolling into AMYPAD PNHS (EPAD LCS, EMIF-AD, ALFA+, FACEHBI, FPACK, UCL, Microbiota, 90+, H70, AMYPAD DPMS-VUmc)
- 1.284 participants recruited of which 1.354 (1138 baseline + 216 EPAD FU) have been scanned.
- Recruitment ongoing. The Last Patient In (LPI) is on the 30th of April 2022.
Updated 29 April 2022